Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Reports 2014 Financial Results
FREMONT, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of
View HTML
Toggle Summary Zosano Pharma to Present at the 27th Annual ROTH Conference
FREMONT, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) announced today that Vikram Lamba, Chief Executive Officer, will provide a company overview at the 27th Annual ROTH Conference on March 9, 2015. The presentation will take place at 10:00 a.m.
View HTML
Toggle Summary Zosano Pharma Announces Pricing of Initial Public Offering
FREMONT, Calif., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) announced today the pricing of its initial public offering of 4,500,000 shares of common stock at a price to the public of $11.00 per share. The shares are scheduled to begin trading on the NASDAQ Capital
View HTML
Toggle Summary Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate
FREMONT, Calif. and INDIANAPOLIS, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Zosano) and Eli Lilly and Company (NYSE:LLY) today announced that they have entered into an exclusive agreement to develop ZP-PTH, Zosano's proprietary formulation of parathyroid hormone 1-34 (PTH) using
View HTML
Toggle Summary Zosano Pharma Appoints Troy Wilson, Ph.D., J.D., to Board of Directors
  Zosano Pharma Appoints Troy Wilson, Ph.D., J.D., to Board of Directors Fremont, California, June 25, 2014 – Zosano Pharma Corporation, a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced the election of Troy
View HTML
Toggle Summary Zosano Pharma Files Registration Statement for Proposed Initial Public Offering
Zosano Pharma Files Registration Statement for Proposed Initial Public Offering Fremont, California, June 24, 2014 – Zosano Pharma Corporation (Zosano) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed
View HTML
Toggle Summary Zosano Pharma, Inc. to Present at the 74th American Diabetes Association (ADA) Scientific Session
CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers
View HTML
Toggle Summary Zosano Pharma Appoints Winnie W. Tso, CPA as Chief Financial Officer
    Zosano Pharma Appoints Winnie W. Tso, CPA as Chief Financial Officer FREMONT, Calif., June 2, 2014 – Zosano Pharma, Inc ., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, today announced the appointment of Winnie
View HTML
Toggle Summary Zosano Pharma, Inc. to Present at the 3rd International Microneedle Conference
Zosano Pharma, Inc. to Present at the 3rd International Microneedle Conference Fremont, CA — May 19, 2014 — Zosano Pharma, Inc ., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced that Dr.
View HTML
Toggle Summary Zosano Pharma Enters into a License Agreement with Novo Nordisk to Deliver Semaglutide Using Zosano's Microneedle Patch System
Zosano Pharma Enters into a License Agreement with Novo Nordisk to Deliver Semaglutide Using Zosano's Microneedle Patch System Fremont, California, February 5, 2014 /PRNewswire/ — Zosano Pharma, Inc., (Zosano) announced today that it has entered into an agreement with Novo Nordisk A/S
View HTML